ArriVent Reports Phase 1 Data For Cancer Drug ARR-217 |

BTCBitcoin$75,949.00▲ 0.24%ETHEthereum$2,240.69▲ 0.42%SOLSolana$90.15▲ 0.56%EUR/USDEUR→USD1.1145 USDGBP/USDGBP→USD1.3355 USDAAPL$342.37▼ 0.52%GC$4,079.50

No results